Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceritinib + nivolumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of ceritinib, a second-generation ALK tyrosine kinase inhibitor, and nivolumab, a PD-1 immune checkpoint inhibitor. This combination is being investigated for the treatment of ALK-positive non-small cell lung cancer (NSCLC). The rationale for combining these agents is based on evidence that ALK signaling can induce PD-L1 expression, suggesting potential synergy between ALK inhibition and immune checkpoint blockade.
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ceritinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceritinib + nivolumab.